ATE274353T1 - Verwendung von aufgereinigtem invaplex als impfstoff für gram-negativebakterien - Google Patents

Verwendung von aufgereinigtem invaplex als impfstoff für gram-negativebakterien

Info

Publication number
ATE274353T1
ATE274353T1 AT99969665T AT99969665T ATE274353T1 AT E274353 T1 ATE274353 T1 AT E274353T1 AT 99969665 T AT99969665 T AT 99969665T AT 99969665 T AT99969665 T AT 99969665T AT E274353 T1 ATE274353 T1 AT E274353T1
Authority
AT
Austria
Prior art keywords
negative bacteria
vaccine
gram negative
invaplex
purified
Prior art date
Application number
AT99969665T
Other languages
English (en)
Inventor
Edwin V Oaks
Kevin Ross Turbyfill
Antoinette Berrong Hartman
Original Assignee
Us Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27379338&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE274353(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Us Army filed Critical Us Army
Application granted granted Critical
Publication of ATE274353T1 publication Critical patent/ATE274353T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/50—Lipopolysaccharides; LPS
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99969665T 1998-09-30 1999-09-28 Verwendung von aufgereinigtem invaplex als impfstoff für gram-negativebakterien ATE274353T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10239898P 1998-09-30 1998-09-30
US10239798P 1998-09-30 1998-09-30
US13619099P 1999-05-27 1999-05-27
PCT/US1999/022772 WO2000018355A2 (en) 1998-09-30 1999-09-28 Use of purified invaplex from gram negative bacteria as a vaccine

Publications (1)

Publication Number Publication Date
ATE274353T1 true ATE274353T1 (de) 2004-09-15

Family

ID=27379338

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99969665T ATE274353T1 (de) 1998-09-30 1999-09-28 Verwendung von aufgereinigtem invaplex als impfstoff für gram-negativebakterien

Country Status (6)

Country Link
US (4) US6245892B1 (de)
EP (1) EP1198245B1 (de)
AT (1) ATE274353T1 (de)
AU (2) AU1199900A (de)
DE (1) DE69919754T2 (de)
WO (2) WO2000018355A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997040161A1 (en) * 1996-04-19 1997-10-30 Henry M. Jackson Foundation For The Advancement Of Military Medecine Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability
US7172762B1 (en) * 1999-01-29 2007-02-06 Pfizer Inc. Erysipelothrix rhusiopathiae antigens and vaccine compositions
GB0025058D0 (en) * 2000-10-12 2000-11-29 Smithkline Beecham Biolog Composition
AU2002314793B2 (en) * 2001-05-18 2007-08-02 Walter Reed Army Institute Of Research Heterologous protection induced by immunization with invaplex vaccine
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
AU2003281909A1 (en) * 2002-11-14 2004-06-03 Instituto Finlay. Centro De Investigacion-Produccion De Vacunas Y Sueros. Method of obtaining conjugate vaccines and vaccine compositions containing same
ES2405506T3 (es) 2003-10-24 2013-05-31 Nora Therapeutics, Inc. Un método para obtener datos útiles en la identificación de un paciente con riesgo de tener dificultad de llevar a término un embarazo
US8338373B2 (en) * 2003-10-24 2012-12-25 Nora Therapeutics, Inc. Method for reducing the risk of spontaneous abortion in a human female subject
US20090226397A1 (en) 2003-10-24 2009-09-10 Nora Therapeutics, Inc. Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
ATE454902T1 (de) * 2003-11-25 2010-01-15 Us Gov Sec Army Verwendung von shigella invaplex für den transport von funktionalen proteinen und transkriptionsaktiven nukleinsäuren durch säugetier-zellmembranen in vitro und in vivo
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US7833740B2 (en) * 2005-08-07 2010-11-16 Tgc Biomics Gmbh Test system for detecting salmonella
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
CA2563214A1 (en) * 2006-10-12 2008-04-12 Institut Pasteur Shigella ipad protein and its use as a potential vaccine against shigella infection
CA2685729C (en) * 2007-03-27 2016-05-31 The United States Of America As Represented By The Secretary Of The Army, Walter Reed Army Institute Of Research Artificial invaplex
US7780966B2 (en) * 2007-03-27 2010-08-24 The United States Of America As Represented By The Secretary Of The Army Artificial invaplex
RU2440136C2 (ru) * 2007-03-27 2012-01-20 Те Юнайтид Стейтс Оф Америка Эз Репризентид Бай Те Секретри Оф Те Арми, Уолтер Рид Арми Инститьют Оф Рисерч Синтетический invaplex
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
SI3831406T1 (sl) * 2010-08-23 2024-08-30 Wyeth Llc Stabilne formulacije antigenov neisseria meningitidis RLP2086
NZ607224A (en) 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
RU2665841C2 (ru) 2012-03-09 2018-09-04 Пфайзер Инк. Композиции neisseria meningitidis и способы их применения
CA2883652C (en) * 2012-09-06 2020-04-14 Eveliqure Biotechnologies Gmbh A novel live attenuated shigella vaccine
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
EP2964665B1 (de) 2013-03-08 2018-08-01 Pfizer Inc Immunogene fusionspolypeptide
BR112016004463A2 (pt) 2013-09-08 2017-10-17 Pfizer composições de neisseria meningitidis e métodos das mesmas
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CN118021947A (zh) 2017-01-31 2024-05-14 辉瑞大药厂 脑膜炎奈瑟菌组合物及其使用方法
MX2022003682A (es) 2019-09-27 2022-04-25 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
CN112831487B (zh) * 2021-01-27 2022-05-06 武汉爱博泰克生物科技有限公司 一种重组蛋白酶k的纯化方法及其应用
CN113466321B (zh) * 2021-08-12 2022-10-14 河北省食品检验研究院 一种产志贺毒素大肠埃希氏菌的分型方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US5589380A (en) * 1992-06-05 1996-12-31 University Of Maryland At Baltimore Isolated DNA molecule encoding SHET1 of Shigella flexneri 2a and mutant Shigella flexneri 2a
US5897475A (en) * 1994-10-05 1999-04-27 Antex Biologics, Inc. Vaccines comprising enhanced antigenic helicobacter spp.
US5972899A (en) * 1996-01-25 1999-10-26 New York University Apoptosis induced by Shigella IpaB
US6261561B1 (en) * 1996-04-19 2001-07-17 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of stimulating an immune response by administration of host organisms that express intimin alone or as a fusion protein with one or more other antigens
AU3755999A (en) * 1998-04-24 1999-11-16 Henry M. Jackson Foundation For The Advancement Of Military Medicine Proteins that direct the secretion of virulence proteins and vaccines comprisingthem

Also Published As

Publication number Publication date
WO2000018354A3 (en) 2001-01-04
EP1198245B1 (de) 2004-08-25
AU1098400A (en) 2000-04-17
US20050013822A1 (en) 2005-01-20
WO2000018354A2 (en) 2000-04-06
WO2000018355A3 (en) 2000-11-23
US6245892B1 (en) 2001-06-12
US6277379B1 (en) 2001-08-21
US20010009957A1 (en) 2001-07-26
AU1199900A (en) 2000-04-17
DE69919754D1 (de) 2004-09-30
EP1198245A2 (de) 2002-04-24
WO2000018355A2 (en) 2000-04-06
DE69919754T2 (de) 2005-09-01
WO2000018355A9 (en) 2001-08-16
US6680374B2 (en) 2004-01-20

Similar Documents

Publication Publication Date Title
DE69919754D1 (de) Verwendung von aufgereinigtem invaplex als impfstoff für gram-negativebakterien
NZ618298A (en) A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
DE69111440D1 (de) Methoden und zusammensetzungen zur impfung gegen hiv.
DE69325454D1 (de) Taxol-derivate
AU3115395A (en) Dihydrobenzofuranes
DE69731285D1 (de) Langwellig fluorezierende proteine
ATE328068T1 (de) Papillomavirus vakzine
ATE211732T1 (de) N-benzylpiperidin- und tetrahydropyridin-derivate
DE69637844D1 (de) Neues tgf-beta-ahnliches cytokin
BG104117A (en) Universally applicable blood plasma
IT1293778B1 (it) 1,4,7,10-tetraazabiciclo(8.2.2.)tetradecan-2 one, sua preparazione e suo uso per la preparazione di tetraazamacrocicli
ATE279940T1 (de) Behandlung und prävention von helicobacter- infektionen
ATE222930T1 (de) Antigene arznei zur behandlung oder vorbeugung
FI972384A0 (fi) Uudet dipeptidiset p-amidinobentsyyliamidit, jotka sisältävät N-terminaalisia sulfonyyli- tai amidinosulfonyyliryhmiä
BG101002A (bg) Заместени арилалкилтио-алкилтиопиридини и използване за борба с бактерии от рода helicobacter
DK0840792T3 (da) (S)-hydroxynitrillyase fra Hevea brasiliensis
DE69728897D1 (de) Saeugetierchemokine
ATE92498T1 (de) Primycinkomponenten und verfahren zur trennung des antibiotischen komplexes.
BRPI0416201A (pt) métodos para purificação de toxina coqueluche e peptìdios neles utilizáveis
ATE185165T1 (de) Gen-expressionssystem
BR0016616A (pt) Microrganismos atenuados para o tratamento de infecção
DK0485463T3 (da) Svækket hundeparvovirus (CPV), vaccine omfattende CPV og fremgangsmåde til forebyggelse af CPV-infektion i hunde
DE69104357D1 (de) Klonierungs- und/oder expressionsvektoren, verfahren zur ihrer herstellung und verwendung.
DE59905355D1 (de) Verwendung von katecholderivaten als proteinaseinhibitoren
BG102535A (en) Dihydrate of (2r,3s)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate of 4,10 beta-diacetoxy-2 alpha-benzoyloxy-5 beta, 20-epoxy-1-hydroxy-9-oxo-19-nor-cyclopropa[g]tax-11-ene 13-alpha -yl and method for its preparaton

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties